Navigation Links
Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
Date:8/8/2012

LONDON, Aug. 8, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control over food intake.

BED is a major cause of obesity for those patients with addictive behavior towards food. It is the most chronic and common of all eating disorders with a significant cost to society, with 12 to 18 million people in the United States likely meeting the criteria for BED and a further 20 million people exhibiting bingeing behavior. It is significantly undertreated with no approved pharmacological therapies.

Patients receiving the naloxone nasal spray achieved the study's primary endpoint by exhibiting a statistically significant reduction in time spent per week binge eating compared to those patients who received a placebo nasal spray, reducing their bingeing by 125 minutes per week compared to 84 minutes per week for placebo-treated subjects (p=0.024).

The effect of the naloxone nasal spray was especially pronounced when comparing the baseline bingeing with the level of bingeing during the last week of treatment, with the patients receiving naloxone reducing their bingeing by 158 minutes per week compared to 101 minutes per week for placebo-treated subjects (p=0.018) during this period. Overall, 81% of patients completed the entire six-month study with no statistically significant difference in dropout rates between the placebo and the treatment groups and without any Serious Adverse Events (SAE) reported during the trial.
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
3. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
6. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
7. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
8. Juventas Therapeutics Raises $22.2 Million Series B Financing
9. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... the 3rd Annual Disruptive Innovations to Advance Clinical Trials ... Copley Plaza Hotel in Boston, MA. , Disruptive ... Janssen Pharmaceuticals and more share bold approaches to reduce ... , “Disruptive innovation needs to be big, or ...
(Date:5/22/2013)... Genedata, a leading provider of advanced ... life science research, today announced AB Enzymes will ... bioinformatics platform for strain genome data management on ... Enzymes, one of the world’s oldest and best-known ... Selector accompanied by bioinformatics consulting services. Genedata Selector, ...
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 Alton ... thetelegraph.com dated May 15, 2013 said that their presence ... help other bed bug sufferers avoid such big spending, My ... bugs inexpensively. , It was said in the report ... an exterminator, MCP related. Apart from that, its employees also ...
(Date:5/21/2013)... England , May 22, 2013 ... novel drug-only formulation of glycopyrronium bromide designed using Prosonix, ... pharmaceutical company developing a portfolio of inhaled Respiratory ... clinical study with PSX1002 that will assess its effect ... of doses in patients with moderate to severe chronic ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... ... Clinical Applications, BOTHELL, Wash., Nov. ... developer and marketer of proprietary,hypothermic storage and cryopreservation media products ... a Master File to the,United States Food and Drug Administration ...
... Nov. 5 On Friday, November 7, 2008,at ... members,of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... conference call to discuss the Company,s 2008,third quarter ... Numbers Friday, November 7 8:30 a.m. ...
... Inc.,(Nasdaq: TELK ) reported a net loss of ... ended September 30, 2008, compared with a net loss ... period in 2007. The,$8.0 million net loss includes a ... with an auction reset feature, or,auction rate securities, which ...
Cached Biology Technology:BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 2BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 3Telik Announces Financial Results for 2008 Third Quarter 2Telik Announces Financial Results for 2008 Third Quarter 3Telik Announces Financial Results for 2008 Third Quarter 4
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... COLUMBIA, Mo. Cancers of all types become most ... body. Once cancer has reached this stage, it becomes ... numerous tumors that can develop. Now, researchers at the ... radioactive nanoparticles that target lymphoma tumor cells wherever they ... professor of oncology in the MU College of Veterinary ...
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2
... Wash. An international team of scientists from Italy, France, ... sequence of the domestic apple genome in the current issue ... genome sequence for apple will allow scientists to more rapidly ... which genes and gene variants provide disease or drought resistance ...
... a chronic and often disabling condition. Despite modern ... to the patients and their relatives and take ... and societal expenditure. The diagnosis of ... structure and changes in neurotransmission, with increased dopamine ...
... (August 27, 2010) Although having a high body ... cardiovascular disease, researchers are only beginning to understand how ... of the disease. Now, a study of a subset ... (KEEPS), suggests that as BMI increases, so do platelet ...
Cached Biology News:Core knowledge of tree fruit expands with apple genome sequencing 2Core knowledge of tree fruit expands with apple genome sequencing 3Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
... Kit has been designed for recovery of DNA from ... Features Ultra fast protocol: DNA is ready ... are easy to resuspend Bead uniformity prevents shearing ... (suitable for PCR) DNA is eluted into sterile ...
... DNA from agarose gels The SpinPrep Gel DNA ... bp to > 12,000 bp in size from agarose ... gel slice, followed by adsorption of the DNA to ... a wash step, the purified DNA is eluted in ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
Biology Products: